Get started
Author

Medhat Osman

Current Status of Clinical 177 Lu-PSMA Radiopharmaceutical Therapies: Insights from a Survey of High-End Nuclear Medicine Theranostic Centers
2026 · Mehdi Djekidel, Lillian Dominguez-Konicki, et al. · Journal of Nuclear Medicine Technology
A phase I/IIa, first-in-human, multicenter, monotherapy and combination therapy with nivolumab dose-finding study of [ 212 Pb]VMT01 melanocortin-1-receptor–targeted, image-guided, alpha-particle therapy in subjects with previously treated unresectable or metastatic melanoma.
2026 · Zachary Scott Morris, Richard L. Wahl, et al. · Journal of Clinical Oncology
PDF
A phase I/IIa, image-guided, alpha-particle therapy study of [ 203 Pb]Pb-PSV359 and [ 212 Pb]Pb-PSV359 in patients with solid tumors that are known to be fibroblast activation protein (FAP)–positive.
2026 · Samuel Mehr, Ravi Patel, et al. · Journal of Clinical Oncology
Phase Ib results from the phase Ib/II study of [ 177 Lu]Lu-DOTA-TATE in combination with standard of care as a first-line treatment for pts with extensive-stage small cell lung cancer.
2026 · Stephen V. Liu, Pedro Rocha, et al. · Journal of Clinical Oncology
PDF
Challenges and Pitfalls in MIBG Imaging: A Systematic Review
2026 · Serin Moghrabi, Ahmed Saad Abdlkadir, et al. · Nuclear Medicine and Molecular Imaging
A phase 1 first-in-human, dose-escalation and -expansion study of RYZ401, a novel radiopharmaceutical therapy (RPT) labeled with actinium-225 ( 225 Ac), in patients with neuroendocrine tumors (NETs) and other solid tumors expressing somatostatin receptors (SSTRs).
2026 · Heloisa P. Soares, Rebecca K.S. Wong, et al. · Journal of Clinical Oncology
Works count: 6
Citation count:
H-index:
I10-index:
Year
Topic
Type